INTUITIVE SURGICAL INC (IUI1.DE) Fundamental Analysis & Valuation

FRA:IUI1 • US46120E6023

Current stock price

405.4 EUR
-2.35 (-0.58%)
Last:

This IUI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. IUI1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year IUI1 was profitable.
  • In the past year IUI1 had a positive cash flow from operations.
  • In the past 5 years IUI1 has always been profitable.
  • In the past 5 years IUI1 always reported a positive cash flow from operatings.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • IUI1 has a Return On Assets of 13.96%. This is amongst the best in the industry. IUI1 outperforms 98.28% of its industry peers.
  • With an excellent Return On Equity value of 16.02%, IUI1 belongs to the best of the industry, outperforming 87.93% of the companies in the same industry.
  • IUI1's Return On Invested Capital of 13.95% is amongst the best of the industry. IUI1 outperforms 91.38% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for IUI1 is above the industry average of 9.41%.
  • The 3 year average ROIC (12.43%) for IUI1 is below the current ROIC(13.95%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROIC 13.95%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • IUI1 has a better Profit Margin (28.38%) than 100.00% of its industry peers.
  • IUI1's Profit Margin has improved in the last couple of years.
  • IUI1's Operating Margin of 29.35% is amongst the best of the industry. IUI1 outperforms 100.00% of its industry peers.
  • IUI1's Operating Margin has improved in the last couple of years.
  • IUI1 has a better Gross Margin (66.00%) than 75.86% of its industry peers.
  • IUI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 29.35%
PM (TTM) 28.38%
GM 66%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. IUI1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
  • The number of shares outstanding for IUI1 has been reduced compared to 1 year ago.
  • The number of shares outstanding for IUI1 has been increased compared to 5 years ago.
  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

2.2 Solvency

  • IUI1 has an Altman-Z score of 40.43. This indicates that IUI1 is financially healthy and has little risk of bankruptcy at the moment.
  • IUI1 has a better Altman-Z score (40.43) than 100.00% of its industry peers.
  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 40.43
ROIC/WACC1.56
WACC8.95%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • IUI1 has a Current Ratio of 4.87. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
  • IUI1 has a Current ratio of 4.87. This is amongst the best in the industry. IUI1 outperforms 94.83% of its industry peers.
  • IUI1 has a Quick Ratio of 3.96. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
  • IUI1 has a Quick ratio of 3.96. This is amongst the best in the industry. IUI1 outperforms 96.55% of its industry peers.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 3.96
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. IUI1.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.92% over the past year.
  • IUI1 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 21.42% yearly.
  • Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 20.51%.
  • The Revenue has been growing by 18.22% on average over the past years. This is quite good.
EPS 1Y (TTM)25.92%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%38.12%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%22.96%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.55% on average over the next years. This is quite good.
  • Based on estimates for the next years, IUI1 will show a quite strong growth in Revenue. The Revenue will grow by 13.00% on average per year.
EPS Next Y14.43%
EPS Next 2Y14.29%
EPS Next 3Y14.44%
EPS Next 5Y13.55%
Revenue Next Year15.78%
Revenue Next 2Y14.84%
Revenue Next 3Y14.6%
Revenue Next 5Y13%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

2

4. IUI1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 49.50, which means the current valuation is very expensive for IUI1.
  • IUI1's Price/Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Earnings ratio is at 27.15. IUI1 is valued rather expensively when compared to this.
  • Based on the Price/Forward Earnings ratio of 40.83, the valuation of IUI1 can be described as expensive.
  • Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 67.24% of the companies are valued more cheaply.
  • The average S&P500 Price/Forward Earnings ratio is at 22.12. IUI1 is valued rather expensively when compared to this.
Industry RankSector Rank
PE 49.5
Fwd PE 40.83
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • IUI1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 65.52% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of IUI1 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 67.92
EV/EBITDA 44.19
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of IUI1 may justify a higher PE ratio.
  • A more expensive valuation may be justified as IUI1's earnings are expected to grow with 14.44% in the coming years.
PEG (NY)3.43
PEG (5Y)2.31
EPS Next 2Y14.29%
EPS Next 3Y14.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IUI1.DE Dividend Analysis

5.1 Amount

  • IUI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IUI1.DE Fundamentals: All Metrics, Ratios and Statistics

INTUITIVE SURGICAL INC

FRA:IUI1 (4/27/2026, 7:00:00 PM)

405.4

-2.35 (-0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-21
Earnings (Next)07-20
Inst Owners88.75%
Inst Owner ChangeN/A
Ins Owners0.46%
Ins Owner ChangeN/A
Market Cap143.99B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts79.02
Price Target525.27 (29.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)-0.42%
PT rev (3m)-1.16%
EPS NQ rev (1m)-0.79%
EPS NQ rev (3m)-0.7%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.86%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)-0.07%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)0.51%
Valuation
Industry RankSector Rank
PE 49.5
Fwd PE 40.83
P/S 16.81
P/FCF 67.92
P/OCF 55.82
P/B 9.49
P/tB 9.7
EV/EBITDA 44.19
EPS(TTM)8.19
EY2.02%
EPS(NY)9.93
Fwd EY2.45%
FCF(TTM)5.97
FCFY1.47%
OCF(TTM)7.26
OCFY1.79%
SpS24.12
BVpS42.71
TBVpS41.79
PEG (NY)3.43
PEG (5Y)2.31
Graham Number88.7191 (-78.12%)
Profitability
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROCE 16.01%
ROIC 13.95%
ROICexc 20.73%
ROICexgc 21.4%
OM 29.35%
PM (TTM) 28.38%
GM 66%
FCFM 24.75%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 79.72%
Cap/Sales 5.36%
Interest Coverage 250
Cash Conversion 83.46%
Profit Quality 87.21%
Current Ratio 4.87
Quick Ratio 3.96
Altman-Z 40.43
F-Score8
WACC8.95%
ROIC/WACC1.56
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)25.92%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%38.12%
EPS Next Y14.43%
EPS Next 2Y14.29%
EPS Next 3Y14.44%
EPS Next 5Y13.55%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%22.96%
Revenue Next Year15.78%
Revenue Next 2Y14.84%
Revenue Next 3Y14.6%
Revenue Next 5Y13%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year35.45%
EBIT Next 3Y21.62%
EBIT Next 5Y17.23%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%

INTUITIVE SURGICAL INC / IUI1.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?

ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.


Can you provide the valuation status for INTUITIVE SURGICAL INC?

ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.


What is the profitability of IUI1 stock?

INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.


How financially healthy is INTUITIVE SURGICAL INC?

The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.


What is the expected EPS growth for INTUITIVE SURGICAL INC (IUI1.DE) stock?

The Earnings per Share (EPS) of INTUITIVE SURGICAL INC (IUI1.DE) is expected to grow by 14.43% in the next year.